ALSO NOTED: Sanofi's patent loss could benefit Momenta; Optimer prices shares; and much more...

> Momenta may be one of the biggest beneficiaries in Sanofi-Aventis' loss of patent protection for the blockbuster Lovenox. Report

> Optimer Pharmaceuticals has priced its IPO share price at $7, below its original expected range. Report

> The Hindustan Times reports that Merck KGaA is seeking bids for its generic drugs unit. Report

> Advanced Cell Technology has acquired the intellectual property assets of Infigen related to somatic cell nuclear transfer, parthenogenesis, and other related technologies. "This tactical acquisition is a part of our long-term plan to become one of the leading companies in the field of regenerative medicine," said William M. Caldwell, IV, CEO of Advanced Cell Technology. Release

> Cell Therapeutics is selling $17.6 million in shares. Release

> Telik and SRI International have signed a development pact covering the testing of Telik's C243 for MS and other autoimmne and inflammatory ailments. Report

And Finally…The first large scale African trial of an HIV vaccine has gotten underway. It's a test-of-concept study. Report

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.